2024-18267. Medical Devices; General Hospital and Personal Use Devices; Classification of the Intravenous Catheter Force-Activated Separation Device  

  • Table 1—Intravenous Catheter Force-Activated Separation Device Risks and Mitigation Measures

    Identified risks to health Mitigation measures
    Delays of therapy due to failure of device to function as expected ( e.g., if separation force too low) Performance data, Non-clinical performance testing, and Labeling.
    Mechanical complications ( e.g., IV dislodgement, IV infiltration, occlusion, and phlebitis events requiring IV replacement) due to failure of device to function as expected ( e.g., if separation force too high) Performance data, Non-clinical performance testing, and Labeling.
    Infection Sterilization validation, Shelf life testing, Non-clinical performance testing, and Labeling.
    Air embolism Non-clinical performance testing, and Labeling.
    ( print page 66560)
    Adverse tissue reaction Biocompatibility evaluation, Pyrogenicity testing, and Non-clinical performance testing.

Document Information

Effective Date:
8/16/2024
Published:
08/16/2024
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final amendment; final order.
Document Number:
2024-18267
Dates:
This order is effective August 16, 2024. The classification was applicable on May 27, 2021.
Pages:
66558-66560 (3 pages)
Docket Numbers:
Docket No. FDA-2024-N-3356
Topics:
Medical devices
PDF File:
2024-18267.pdf
CFR: (1)
21 CFR 880